Skip to main content
Blood platelets forming clot

EKOS™ Endovascular System

Clinical evidence

The data behind the smart choice

A reputation built on data

No pulmonary embolism interventional therapy has been studied as much as EKOS. EKOS is the only interventional device to treat PE that provides efficacy and safety data with long-term outcomes. The evidence is in the data—and in the over 90,000 patients who have benefitted from the procedure.

Checklist icon


Clinical trials

Magnifying glass with multi-colored bars


Patients studied

Person with heart icon


Patients treated

2 MB
Download clinical data guide

A decade committed to clinical advancement

  • 2014 ULTIMA – Level 1 PE
    data published
  • 2015 SEATTLE II – Pivotal PE trial published
  • 2018 OPTALYSE PE – Optimized PE
    protocol; long-term patient outcomes
  • 2021 KNOCOUT PE Registry
    OPTALYSE protocol adoption & additional data collection
  • 2024 HI-PEITHO – First & largest of its kind in PE

Safety or efficacy is not a choice

You can have both with EKOS. See highlights and detailed data points behind some of the most critical studies in PE interventional treatment.

The OPTALYSE trial results

The SEATTLE II trial results

The ULTIMA trial results

The future of EKOS clinical evidence

With the goal of gaining a deeper understanding of intervention for treating PE, Boston Scientific continues to invest in clinical studies. 


HI-PEITHO represents the first-ever large-scale transatlantic, multi-center, prospective, randomized, controlled trial for an interventional device in pulmonary embolism (PE). It has been designed to address critical gaps in clinical evidence by comparing the clinical benefit of intervention with EKOS vs anticoagulation alone.

icon of open envelope with letter

Stay up to date

Receive emails on the latest advances, EKOS clinical data and news.